You are here
Poor response to second-line kinase inhibitors in CML patients with multiple low-level mutations, irrespective of their resistance profile
Wendy T Parker, Musei Ho, Hamish S Scott, Timothy P Hughes, Susan Branford.
Specific imatinib-resistant BCR-ABL1 mutations (Y253H, E255K/V, T315I, F317L, F359V/C) predict failure of second-line nilotinib and/or dasatinib therapy in CML patients....
http://bloodjournal.hematologylibrary.org/content/early/2011/12/30/blood-2011-08-375535.abstract